journal
MENU ▼
Read by QxMD icon Read
search

Leukemia Research

journal
https://read.qxmd.com/read/30986630/management-and-outcome-of-11-pregnancies-in-women-with-polycythemia-vera
#1
LETTER
E M Elli, E Diral, C Gambacorti-Passerini, R Calori, I Carmosino, M Breccia, R Latagliata, A Di Veroli
No abstract text is available yet for this article.
April 8, 2019: Leukemia Research
https://read.qxmd.com/read/30981853/clinical-presentation-and-prognosis-of-immunoglobulin-light-chain-amyloidosis-with-high-percentage-of-bone-marrow-plasma-cells
#2
Cong-Li Zhang, Yu Qiu, Kai-Ni Shen, Hui-Lei Miao, Jun Feng, Xin-Xin Cao, Lu Zhang, Xian-Yong Jiang, Dao-Bin Zhou, Jian Li
OBJECTIVE: To summarize the clinical features and outcomes in Chinese patients with immunoglobulin light-chain (AL) amyloidosis with ≥10% bone marrow plasma cells (BMPCs). METHODS: We retrospectively compared the clinical features and outcomes between patients with ≥10% BMPCs (high-BMPC group; n = 56) and those with <10% BMPCs (low-BMPC group; n = 311). RESULTS: Patients in the high-BMPC group had significantly higher levels of N-terminal pro-brain natriuretic peptide, significantly lower levels of 24 h urine protein, and significantly higher levels of difference between the involved and uninvolved serum free light chains (485...
April 8, 2019: Leukemia Research
https://read.qxmd.com/read/30981418/compound-mutations-in-cml-imaginary-bogeyman-or-real-arch-nemesis
#3
EDITORIAL
David T Yeung
No abstract text is available yet for this article.
April 6, 2019: Leukemia Research
https://read.qxmd.com/read/30978435/relevant-updates-in-systemic-mastocytosis
#4
REVIEW
Alexander Coltoff, John Mascarenhas
Systemic Mastocytosis (SM) is a rare myeloproliferative neoplasm (MPN) that is characterized by a clonal proliferation of mast cells (MCs). The symptoms and clinical presentation of SM are the result of both MC proliferation as well as activation and degranulation, causing hyperactive and over-exaggerated hypersensitivity responses, as well as organ infiltration by pathogenic MCs. The clinical presentation and course of SM is varied and organ involvement can lead to significant morbidity and mortality in some cases...
April 4, 2019: Leukemia Research
https://read.qxmd.com/read/30978434/autograft-immune-content-and-survival-in-non-hodgkin-s-lymphoma-a-post-hoc-analysis
#5
Luis F Porrata, David J Inwards, Stephen M Ansell, Ivana N Micallef, Patrick B Johnston, Jose C Villasboas, Svetomir N Markovic
The infusion of autograft absolute lymphocyte and monocyte counts affect survival in patients undergoing autologous peripheral hematopoietic stem cell transplantation (APHSCT). However, the specific autograft immune effector cells affecting survival post-APHSCT are unknown. Thus, we performed an ad hoc analysis from our published double-blind, randomized phase III clinical trial in non-Hodgkin's lymphoma (NHL) patients, looking at the infused autograft immune effector cells and their relationship with clinical outcomes post-APHSCT...
April 4, 2019: Leukemia Research
https://read.qxmd.com/read/30955853/patients-perspectives-on-the-definition-of-cure-in-chronic-myeloid-leukemia
#6
LETTER
Kathryn E Flynn, Michael J Mauro, Gemlyn George, Alexander Hinman, Arielle Baim, Vamsi Kota, Richard A Larson, Jeffrey H Lipton, James E Thompson, Martha Wadleigh, Ehab Atallah
No abstract text is available yet for this article.
March 28, 2019: Leukemia Research
https://read.qxmd.com/read/30925311/high-rasd1-transcript-levels-at-diagnosis-predicted-poor-survival-in-adult-b-cell-acute-lymphoblastic-leukemia-patients
#7
Shujuan Wang, Chong Wang, Weiqiong Wang, Qianqian Hao, Yanfang Liu
B-cell acute lymphoblastic leukemia (B-ALL) in adults remains a highly challenging disease. Identifying new prognostic biomarkers is necessary to help select the best therapeutic schedules and to improve prognosis. We performed bioinformatics analyses of transcriptomic data to identify aberrantly-expressed mRNA transcripts in B-ALL and focused on RASD1 (Ras-related dexamethasone-induced 1). To date, no information is available on the prognostic value of RASD1 in B-ALL. Fifty-three consecutive adults with de novo B-ALL were enrolled in this study...
March 20, 2019: Leukemia Research
https://read.qxmd.com/read/30884372/mutations-in-the-dna-methylation-pathway-predict-clinical-efficacy-to-hypomethylating-agents-in-myelodysplastic-syndromes-a-meta-analysis
#8
Mengyi Du, Fen Zhou, Runming Jin, Yu Hu, Heng Mei
PURPOSE: Myelodysplastic syndromes (MDS) are characterized by variable degrees of clinical outcomes. Until now, hypomethylating agents (HMAs) are the only drugs that have been approved by FDA in remedying this complicated prognosis disease, but without satisfactory outcome. So, biomarkers of better clinical outcome are of great significance. Many studies have already reported the potential prognostic value of DNA methylation pathway related gene (TET2/DNMT3 A/IDH) mutations in demethylation therapy patients, with controversial results...
March 2, 2019: Leukemia Research
https://read.qxmd.com/read/30852438/low-ferroportin-expression-in-aml-is-correlated-with-good-risk-cytogenetics-improved-outcomes-and-increased-sensitivity-to-chemotherapy
#9
Maura Gasparetto, Shanshan Pei, Mohammad Minhajuddin, Brett Stevens, Clayton A Smith, Paul Seligman
Iron metabolism is altered in a variety of cancers; however, little is known about the role of iron metabolism in the biology and response to therapy of acute myeloid leukemia (AML). Here we show that SLC40A1, the gene encoding the iron exporter ferroportin (FPN), is variably expressed among primary AMLs and that low levels are associated with good prognosis and improved outcomes. In particular, core binding factor (CBF) AMLs, which are associated with good outcomes with chemotherapy, consistently have low level of SLC40A1 expression...
February 28, 2019: Leukemia Research
https://read.qxmd.com/read/30831481/the-value-of-fdp-fib-and-d-dimer-fib-ratios-in-predicting-high-risk-apl-related-thrombosis
#10
LETTER
Yanliang Bai, Mingyue Shi, Xiawan Yang, Wanjun Zhang, Ruyu Yang, Xiuli Wei, Xudong Wei, Lijuan Duan, Chenghua Wang, Ruihua Mi, Hafiz Abdul Waqas Ahmed, Lei Huo, Yuqing Chen, Fangfang Xu, Depei Wu, Kai Sun
Hemorrhage is the typical manifestation of APL-related coagulopathy while thrombosis is infrequently reported. In a retrospective analysis with 33 patients with hyperleukocytic APL, we found 6 out of 33 hyperleukocytic APL patients presented with thrombosis rather than hemorrhage. A notable feature in these high-risk APL patients with thrombosis is that there were no significant abnormalities in fibrinogen (FIB), prothrombin time (PT) and activated partial thromboplastin time (APTT). Compared with the normal ranges, both the high-risk APL patients with thrombosis and the high-risk APL patients with hemorrhage had a significant increase in fibrinogen degradation product (FDP) and d-dimer levels...
February 22, 2019: Leukemia Research
https://read.qxmd.com/read/30827724/predicting-response-to-new-drugs-in-aml-from-simulation-modelling-value-of-the-beat-aml-project-as-a-validation-resource
#11
EDITORIAL
Brooks Benard, Daniel Thomas
No abstract text is available yet for this article.
February 22, 2019: Leukemia Research
https://read.qxmd.com/read/30831479/replicative-senescence-of-hematopoietic-cells-in-patients-with-idiopathic-cytopenia-of-undetermined-significance
#12
Dong-Yeop Shin, Jin Kyun Park, Chih Chiao Li, Hee Sue Park, Soo Young Moon, Sung-Min Kim, Kyongok Im, Yoon Hwan Chang, Sung-Soo Yoon, Dong-Soon Lee
We hypothesized that a subset of idiopathic cytopenia of undetermined significance (ICUS) is associated with an increased autonomous proliferation with exhaustion of hematopoiesis. The aim of this study was to investigate the cell turnover rate and replicative history of the bone marrow cells of ICUS patients. To this end, we examined telomere length (TL), proliferation, and apoptosis of the bone marrow cells of ICUS patients and healthy controls (HCs) using telomere quantitative fluorescence in situ hybridization and immunohistochemical staining for Ki-67 and cleaved caspase-3...
February 18, 2019: Leukemia Research
https://read.qxmd.com/read/30797139/prospective-observational-study-in-comorbid-patients-with-chronic-lymphocytic-leukemia-receiving-first-line-bendamustine-with-rituximab
#13
Martin Špaček, Petra Obrtlíková, Stanislava Hrobková, Eduard Cmunt, Josef Karban, Jan Molinský, Martin Šimkovič, Heidi Mociková, Lekaa Mohammadová, Anna Panovská, Jan Novák, Marek Trněný, Lukáš Smolej, Michael Doubek
Chemoimmunotherapy with bendamustine and rituximab is an alternative treatment for elderly patients with CLL. The aim of this observational multicenter study was to prospectively assess efficacy and safety of bendamustine and rituximab in front-line therapy in patients with CLL and significant comorbidities in real hematological practice. Eighty-three consecutive patients with cumulative illness rating scale (CIRS) >6 who received at least one cycle of BR as first-line treatment were included in the study...
February 15, 2019: Leukemia Research
https://read.qxmd.com/read/30776648/the-spectrum-of-musculoskeletal-symptoms-in-patients-with-chronic-myeloid-leukemia-after-stopping-tyrosine-kinase-inhibitors
#14
LETTER
Maria Diab, Charles A Schiffer
No abstract text is available yet for this article.
February 11, 2019: Leukemia Research
https://read.qxmd.com/read/30784762/pak1-gene-functioned-differentially-in-different-bcr-abl-subtypes-in-leukemiagenesis-and-treatment-response-through-stat5-pathway
#15
Ye Yuanxin, Zhou Yanhong, Zheng Qin, Tang Sishi, Dai Yang, Zhou Yi, Wang Minjin, Zhou Juan, Lu Xiaojun, Wang Lanlan, Ying Binwu
The BCR-ABL fusion gene (BCR-ABL) has different subtypes such as p210 and p190 with p190 appear to lead to a worse prognosis. To explore the mechanism of difference in pathogenesis and prognosis in different BCR-ABL subtype-related leukemia, expression profile microarray analysis was conducted between p190 and p210 patients and verified by RT-PCR. The p21-activated kinase (PAK1) gene was chosen and regulation of the PAK1-STAT5 biological axis and its influence on proliferation and apoptosis in leukemia cells were also analyzed...
January 24, 2019: Leukemia Research
https://read.qxmd.com/read/30773246/flow-cytometry-diagnosis-in-myelodysplastic-syndrome-current-practice-in-latin-america-and-comparison-with-other-regions-of-the-world
#16
S Grille, M Iastrebner, I Lorand-Metze, V H J van der Velden, M R V Ikoma, G Vidal-Senmache, E Colado, L J Rabelo-Carrasco, A Blanco, F Huamán-Garaicoa, J E O'Connor, C Cao Pochintesta, E Jensen, N S Bacal, L Díaz, D Lens
BACKGROUND: Flow cytometry (FC) is a valuable tool for the diagnosis of myelodysplastic syndromes (MDS). We present results of a survey carried out to evaluate FC current practice for MDS diagnosis in Latin America (LA), focusing on markers used and characteristics of the clinical diagnostic report. Compliance to IMDSflow recommendations was also evaluated. These practices were then compared with those used in other countries. METHODS: An online survey was sent through the Grupo Latino-Americano de Mielodisplasia to LA cytometrists and other international scientific societies...
January 24, 2019: Leukemia Research
https://read.qxmd.com/read/30954622/not-type-of-induction-therapy-but-consolidation-with-allogeneic-hematopoietic-cell-transplantation-determines-outcome-in-older-aml-patients-a-single-center-experience-of-355-consecutive-patients
#17
Jacobien Hilberink, Carin Hazenberg, Eva van den Berg, André Mulder, Jan Jacob Schuringa, Lieke van der Helm, Marco de Groot, Goda Choi, Geertruida H de Bock, Edo Vellenga, Emanuele Ammatuna, Gerwin Huls
Therapeutic decision making is often challenging in older AML patients. We collected retrospective data of 355 consecutive AML patients (≥60 years) who were treated with intensive chemotherapy (IC) (n = 155), hypomethylating agents (HMA) (n = 83), or best supportive care (BSC) (n = 117) between 2002 and 2017. Overall survival (OS) and response rates after therapy were analyzed. Multivariate Cox regression was performed to analyze the impact of different treatment strategies on survival. The median OS was not significantly different between patients treated with IC or HMA (14...
May 2019: Leukemia Research
https://read.qxmd.com/read/30908982/aplastic-anemia-mds-international-foundation-aa-mdsif-bone-marrow-failure-disease-scientific-symposium-2018
#18
Kerri Becktell, Deborah Berlyne, Simona Pagliuca, Lauren Pommert, Pedro H Prata, David Margolis, Régis Peffault de Latour, Carlo Dufour, Filomena Pierri
The bone marrow failure (BMF) syndromes are a group of rare disorders characterized by ineffective hematopoiesis resulting from deficiencies in the hematopoietic stem cell compartment. Although these diseases are typically acquired, some forms (e.g., Fanconi anemia, dyskeratosis congenita, Diamond Blackfan anemia, and Shwachman Diamond syndrome) are inherited. Patients with BMF syndromes can develop peripheral blood cytopenias and pancytopenia, and their disease can ultimately progress to acute myelogenous leukemia (AML)...
May 2019: Leukemia Research
https://read.qxmd.com/read/30852300/improving-risk-stratification-of-patients-with-chronic-lymphocytic-leukemia-using-multivariate-patient-similarity-networks
#19
Peter Turcsanyi, Eva Kriegova, Milos Kudelka, Martin Radvansky, Lenka Kruzova, Renata Urbanova, Petra Schneiderova, Helena Urbankova, Tomas Papajik
BACKGROUND: Better risk-stratification of patients with chronic lymphocytic leukemia (CLL) and identification of subsets of ultra-high-risk (HR)-CLL patients are crucial in the contemporary era of an expanded therapeutic armamentarium for CLL. METHODS: A multivariate patient similarity network and clustering was applied to assess the prognostic values of routine genetic, laboratory, and clinical factors and to identify subsets of ultra-HR-CLL patients. The study cohort consisted of 116 HR-CLL patients (F/M 36/80, median age 63 yrs) carrying del(11q), del(17p)/TP53 mutations and/or complex karyotype (CK) at the time of diagnosis...
April 2019: Leukemia Research
https://read.qxmd.com/read/30851544/programmed-cell-death-receptor-pd-1-ligand-pd-l1-expression-in-philadelphia-chromosome-negative-myeloproliferative-neoplasms
#20
Jen-Chin Wang, Chi Chen, Ajay Kundra, Sreenath Kodali, Anita Pandey, Ching Wong, Tony Cheung, Vladimir Gotlieb, Gardith Joseph, Sophia Tribie
Programmed Cell Death Receptor (PD-1) and its Ligand (PD-L1) pathway inhibitor therapy has been explored in the field of oncology treatment mainly for solid tumors. In hematologic malignancies, there is limited information except for Hodgkin's lymphoma, and there is even less information regarding myeloproliferative neoplasm (MPN). Therefore, we explored this by first measuring PD-1 and PD-L1 levels (percentage of positive cells) in 63 patients with Philadelphia chromosome-negative MPN (Ph(-) MPN), including 16 MF (12 PMF, 2 post-PV-MF, 2 post-ET-MF), 29 ET, and 18 PV...
April 2019: Leukemia Research
journal
journal
27133
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"